Rubicon’s Current Programs

Rubicon is working closely with our collaborator network to develop our two platform technologies in a variety of indications as shown below.

Our Fv-Hsp72 technology’s ability to directly deliver therapeutic quantities of Hsp72 into stressed and damaged cells makes it an ideal candidate for multiple acute indications.

Our Modified Annexin technology has broad applications in cancer treatment since it will target a membrane phospholipid commonly found on solid tumors and tumor vasculature.